

Subject: [OC081] Acceptance Letter (Mr. MUDDATSTSIR IDRIS, Institut Teknologi Sepuluh Nopember)

Dear Author,

Congratulations! Your abstract submitted for the **5th International Seminar on Chemistry 2022 (ISoC V)** has been approved by the organizing committee.

Title : **Phytochemical Screening and Cytotoxicity of Melastoma malabathricum L. Leaves Extracts Against MCF-7, HeLa, A549, B16, and HT29 Cells**

Presenter : **Mr. MUDDATSTSIR IDRIS**

Type of presentation : **Oral**

Mode of presentation : **Online**

The registration fee : **IDR 405.000**

Please be informed that selected papers will be considered for publication in **Scopus Indexed** journals. To ensure your paper is considered for publication, you are required to submit your **FULL PAPER** by **30th September 2022**. The details of the publication can be found on the webpage.

Kindly acknowledge receipt of this email as early as possible. You are required to complete your payment by **25th September 2022**. Please send the proof of payment by filling this form (<https://bit.ly/Paymentproofisoc>).

For any further assistance please feel free to contact us at (+6281263126418).

Thank you.

Best regards,

Secretariat of ISoC V 2022

Department of Chemistry, Faculty of Science and Data Analytics

Institut Teknologi Sepuluh Nopember (ITS)

E-mail: isoc.its@gmail.com

website: <http://isoc-its.id>

Surabaya, 22th November 2022

Journal/Proceedings: AIP Conference Proceedings

Title: Phytochemical Screening and Cytotoxicity of *Melastoma malabathricum* L. Leaves
Extracts Against MCF-7, HeLa, A549, B16, and HT29 Cells

Abstract Number: OC081

Dear Muddatstsir Idris

Thank you very much for submitting your manuscript to **[AIP Conference Proceedings]** via the International Seminar on Chemistry 2022 with ID Number of **[OC081]**.

Submission Title: Phytochemical Screening and Cytotoxicity of *Melastoma malabathricum* L. Leaves Extracts Against MCF-7, HeLa, A549, B16, and HT29 Cells

Currently your manuscript is under review by the ISoC committee before being processed for further journal submission


The ISoC committee will inform the result of the review process later in your email. If you have any question, please do not hesitate to contact us.

Thank You.

Best Regards,




Organizing Committee







International Seminar on Chemistry 2022 (ISoC 2022)

yahoo!mail Temukan pesan, dokumen, foto, atau orang Lanjutan  MUDDAT...


Tulis

Email Masuk 205

- Belum Dibaca
- Berbintang
- Draft 1
- Terkirim
- Arsip
- Spam
- Sampah
- ^ Lebih sedikit
- Tamp... Sembunyikan
-  Foto
-  Dokumen
-  Langganan
- Folder Sembunyikan

← Kembali   →  Arsipkan  Pindahkan  Hapus  Spam ...

• ISoC2022: REVISION ROR AIP CONFERENCE PROCEEDINGS Yahoo/Email M... ☆

 **ISOC Seminar**
Dari: isoc.its@gmail.com
Kepada: mu_idris74@yahoo.com Sab, 11 Feb 2023 jam 14.56 ☆

Dear Author,

On behalf of the ISoC2022 Committee, we are pleased to inform you that your submitted full paper has been reviewed by experts in the fields. The reviewer recommends reconsideration of your manuscript following minor/major revision and modification.

Please correct your manuscript based on the reviewer's comment(s), and highlight changes in your manuscript. When revising your manuscript, please consider all issues mentioned in the reviewer's comments carefully. Please outline every change made in response to their comments not addressed and please attach Plagiarism report, which must be less than 20%. Please note that your revised submission may need to be re-reviewed.

Please resubmit your revised manuscript with Plagiarism report less than 20% to isoc.its@gmail.com before 25 February 2023.

The ISoC committee values your contribution and look forward to receiving your revised manuscript.

Thank you,

FORM REVIEW ISoC 2022

Title : **Phytochemical Screening and Cytotoxicity of Melastoma malabathricum L. Leaves Extracts Against MCF-7, HeLa, A549, B16, and HT29 Cells**

Paper ID : OC081

Comments :

General

- 1) The English must be properly checked and revised.

Abstract

The abstract provides a clear and concise summary of the article. The abstract should include a background for the work, a brief description of the methods, a summary of the results, and a conclusion.

Introduction

1. The introduction is not interesting due to lack of previous studies and not enough background, especially the description of *Melastoma malabathricum* and the recent report for its cytotoxicity from different parts of this plant.
2. The objectives and aims of this study were not mentioned.

Materials and Methods

- 1) *Escherichia coli* >>> *E. coli* and for all bacteria, animals, plants.
- 2) Provide the specimen number from plant determination.
- 3) Provide reference(s) for terpenoid test.

Results and Discussion

- 1) Table 1 >>> provide the (+) and (-) sign interpretation as foot note below the table.
- 2) Provide reference(s) for phytochemical screening discussion.
- 3) Terpenoids were found in methanol extracts >>> reference(s) must be provided.
- 4) How was the methanol extract selected for cytotoxicity against the five cell lines?. Please describe and insert in the discussion.
- 5) Provide more discussion and reference(s) for methanol extract against HT29 cell line (the most significant cytotoxicity result among others).
- 6) More discussion for all the findings and data elaboration are needed in this section.

Conclusions

Conclusion states the significance of the study and its potential impact. Conclusion must be supported by results.

References

Please update the references

Recommendation: **MAJOR REVISION**

Phytochemical Screening and Cytotoxicity of *Melastoma malabathricum* L. Leaves Extracts Against MCF-7, HeLa, A549, B16, and HT29 Cells

Muddatstsir Idris^{1,2)}, Adi Setyo Purnomo¹⁾, Fahimah Martak¹⁾, Sri Fatmawati^{1,3,a)}

¹ Department of Chemistry, Faculty of Science and Data Analytics, Institut Teknologi Sepuluh Nopember, Jalan Arif Rahman Hakim, Sukolilo, Surabaya 60111, East Java, Indonesia

² Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Lambung Mangkurat, A. Yani KM. 35.8 Banjarbaru 70714, South Kalimantan, Indonesia

³ Agri-food and Biotechnology Research Center, Institut Teknologi Sepuluh Nopember, Jalan Arif Rahman Hakim, Sukolilo, Surabaya 60111, East Java, Indonesia

^{a)} Corresponding Author

E-mail Address: fatma@chem.its.ac.id

Abstract. A medicinal plant widely distributed in South Kalimantan, Indonesia, is *Melastoma malabathricum*. Therefore, this research aimed to assess the phytochemicals (terpenoid, steroid, flavonoid, and alkaloid contents) and cytotoxicity of *M. malabathricum* leaves extracts in order to investigate *M. malabathricum* as a medicinal plant for anticancer agents. Using phytochemical screening techniques, the terpenoid, steroid, alkaloid, and flavonoid contents were examined. A cytotoxicity test was conducted *in vitro* on several cancer cell lines, such as MCF-7, HeLa, and A549. B16, and HT29. *M. malabathricum* leaves extract contains terpenoids, steroids, alkaloids, and flavonoids. MCF-7, HeLa, A549, B16, and HT29 cancer cell lines were used to demonstrate the cytotoxicity of the methanol extract, with IC₅₀ values of 327.37±0.67, 327.05±0.48, 304.46±1.93, 319.21±0.67, and 1.43±0.19 µg/mL, respectively. These findings suggest that the plant could serve as a promising source of anticancer agents.

INTRODUCTION

Cancer is a menacing and lethal disease for which the discovery of effective drugs that do not cause harmful side effects is still being sought to date. It is characterized by uncontrolled cell growth invading healthy tissue [1]. Numerous plant species have been used in the treatment and prevention of cancer, with approximately 3,350 species used in ethnomedicine [2].

As an herbal medicine, *M. malabathricum* has been traditionally used for a long time. In Malaysia, the leaves and roots have been utilized for treating wounds, postnatal care, and preventing scars from smallpox infections, as well as for the treatment of stomach ulcers, dysentery, and diarrhea. The Melastomataceae family, to which *M. malabathricum* belongs, exhibits various bioactivities such as antioxidant, anticancer, cytotoxic, anti-hypertensive, and anti-nociceptive, antipyretic, antiviral, anti-inflammatory, antibacterial, as well as antifungal properties [3]. The leaves of *M. malabathricum* contain tannins, saponins, triterpenes, flavonoids, and steroids [4].

The IC₅₀ value for the DPPH antioxidant activity demonstrated by the *M. malabathricum* flower methanol extract was 17.23 µg/mL [5]. Furthermore, methanol and chloroform flower extracts showed anticancer activity against the MCF-7 cell line with 45.76 and 33.63 µg/mL IC₅₀ after 72 hours of testing, respectively [3]. Compound isolates, kaempferol-3-O-(2",6"-di-O-p-trans-coumaroyl)-β-glucoside as well as naringenin, acquired from the flower ethyl acetate extract exhibited cytotoxicity against the MCF-7 cell line, with respective 1.3 µM and 0.28 µM IC₅₀ values, as stated in reference [6]. The administration of methanol extract from *M. malabathricum*

leaves does not cause death, behavioral irregularities, weight changes, and changes in food and water intake. The results suggest that *M. malabatricum* leaves can be safely consumed orally at both subacute and subchronic levels. Moreover, the extract may have cytotoxic effects against HT29 colon cancer cells through apoptosis [7]. Previously, *M. malabathricum* leaves were investigated because of their antioxidant properties (DPPH, ABTS, as well as FRAP) and phenolic and flavonoid content using various extracts, including methanol, *n*-hexane, dichloromethane, and ethyl acetate. The highest total phenol content was found in the methanol extract, which measured 183.71 ± 0.11 mg GAE/g extract. The highest total flavonoid concentration was found in the ethyl acetate extract, measuring 24.10 ± 0.04 mg QE/g extract. Methanol extract demonstrated the strongest ABTS, DPPH, and FRAP activity, with IC_{50} values of 4.59 ± 0.03 μ g/mL, 8.58 ± 0.03 μ g/mL, and $51.150.10$ M Fe^{+2} /g, respectively. Furthermore, the strongest anti- α -glucosidase and anti- α -amylase activities were found in the anti-diabetic test *in vitro* from methanol extract, with IC_{50} values of 75.25 ± 1.60 and 52.38 ± 1.32 μ g/mL, respectively. According to the *in vivo* antidiabetic test, administering 200 mg/Kg body weight of methanol extract from *M. malabathricum* leaves resulted in a reduction of glucose and serum levels in rat, with values of 51% and 37.82%, respectively, according to reference [8]. Therefore, this research aimed to explore medicinal plants in South Kalimantan, Indonesia, and as such to evaluate the content of terpenoids, steroids, alkaloids, and flavonoids using *M. malabathricum* leaves extracts phytochemical screening as well as to ascertain the cytotoxicity of methanol extract on MCF-7, HeLa, A549, B16, and HT29 cells.

MATERIAL AND METHODS

Plant Material

The leaves of *M. malabathricum* were collected in June 2019 at Banjarbaru, South Kalimantan, Indonesia, and identified by Mr Edi Suroto, a botanist at Purwodadi Botanical Garden, Pasuruan, Indonesia. The voucher specimen was deposited at the Institut Teknologi Sepuluh Nopember's Laboratory of Natural Products and Synthetic Chemistry, with the reference number 013/VI/HT-KIBAS/2019.

Cell lines

The cell lines used were B16-F10 (ATCC CRL-6475) a skin melanoma, A549 (ATCC CCL-185) a lung carcinoma, Breast adenocarcinoma MCF-7 (ATCC HTB-22), cervical adenocarcinoma HeLa (ATCC CCL-2), and colon HT29 (ATCC HTB-38). The Central Laboratory of Pajajaran University in Bandung, Indonesia provided the MCF-7, HeLa, A549, and B16 cells. HT-29 was obtained from the Biomedical Central Laboratory, Faculty of Medicine, Brawijaya University, Malang, Indonesia.

Extraction

The dried leaves of *M. malabathricum* dried leaves extraction involved the use of 20 g of plant material and 250 ml each of ethyl acetate (EA), *n*-hexane (HX), methylene chloride (MC), as well as methanol (MeOH), with an extraction duration of 24 hours. The resultant extract was concentrated on a rotary evaporator and then filtered using filter paper.

Flavonoid Test

The liquid filtrate of the extract received approximately 5 mL of liquid ammonia and then had 1 mL of concentrated sulfuric acid added to it. The appearance of a yellow color, as reported in the reference, indicated the existence of flavonoids [9].

Alkaloid Test

Two test tubes were labeled A and B, and 1 mL of extract was added to each tube. To tube A, 0.5 mL of 2% v/v hydrochloric acid was added and shaken until homogenous. Subsequently, 2-3 drops of Meyer reagent were added to tube A. On the other hand, Wagner reagent was put to tube B in 2-3 drops. The white precipitate formation in tube A and a brown precipitate in tube B indicated the presence of alkaloids in the extract, according to reference [10].

Terpenoid Test

2 mL of 98% chloroform were added to a reaction tube after 1 mL of extract, and the mixture was agitated. The chloroform layer was isolated, and a few drops were put on a drip plate and left to dry. Next, 5 drops of 98% anhydrous acetic acid and 3 drops of 98% sulfuric acid were added to the extract. As described in the reference, the appearance of a red, orange, or yellow color signaled the existence of terpenoids, while a green color formed in the extract indicated the occurrence of steroid [11].

***In vitro* Cytotoxicity Assay**

The *in vitro* cytotoxicity of *M. malabathricum* extracts against various cancer cell lines was assessed using the PrestoBlue (PB) method, including the HeLa (human cervix adenocarcinoma), A549 (human lung carcinoma), MCF-7 (human breast adenocarcinoma), B16 (murine melanoma), as well as HT29 [12]. A full RPMI (Roswell Park Memorial Institute) medium with antibiotics in 50 μ L/50 mL and 10% (v/v) FBS (Fetal Bovine Serum) were used to maintain the cells. Moreover, cell cultures were cultured in 96-well plates at a density of 170,000 cells/mL of medium and incubated for 24 hours at 37°C with 5% CO₂. The samples were then transferred to a brand-new medium and cultured for an additional 48 hours at concentrations ranging from 2.34 to 300 μ g/mL. The medium was then mixed with PB reagent from Thermo Fisher Scientific in Uppsala, Sweden, and the mixture's 570 nm absorbance was measured using a multimode reader. As a positive control, cisplatin was utilized.

RESULTS AND DISCUSSION

Phytochemical Test

Table 1 displays the results of phytochemical tests conducted on extracts of *M. malabathricum* leaves obtained through extraction with methanol (MeOH), *n*-hexane (HX), methylene chloride (MC), as well as ethyl acetate (EA).

TABLE 1. Phytochemical test of *M. malabathricum* leaf extracts

Test	<i>M. malabathricum</i> Leaves Extract			
	HX	MC	EA	MeOH
Terpenoid	+	-	-	+
Steroid	-	+	+	-
Alkaloid	+	+	+	+
Flavonoid	+	+	+	+

Secondary metabolites are present in positive (+) but are absent in negative (-).

M. malabathricum leaves extract contains secondary metabolites (alkaloids, flavonoids, terpenoids, as well as steroids) are shown in the Table 1. Subsequently, terpenoids are mostly found in non-polar but also in polar (methanol extract) because methanol is a polar solvent, hence, can extract both polar and nonpolar compounds. In the *M. malabathricum* leaves methanol extract, terpenoid compounds (β -sitosterol as well as -sitosterol-3-O- β -D-glucopyranoside) were discovered, according to Jofry et al. (2012) [13]. In addition, polar, semi-polar, and non-polar extracts all contain alkaloids and flavonoids. A flavonoid known as quercetin was sequestered from the *M. malabathricum* leaves using *n*-hexane extract [13]. Previous research conveyed that the *M. malabathricum* leaves extract contains flavonoids as well as terpenoids. The leaf extracts of *n*-hexane, methylene chloride, ethyl acetate, as well as methanol had flavonoid contents of 16.77 ± 0.05 , 22.69 ± 0.04 , 24.10 ± 0.04 , and 23.18 ± 0.05 , (mg QE/g Extract) respectively. Meanwhile, the amount of phenols in the leaves extract of *n*-hexane, methanol, methylene chloride, as well as ethyl acetate were 26.97 ± 0.19 , 183.71 ± 0.11 , 27.21 ± 0.17 , and 78.87 ± 0.14 (mg GAE/g Extract), respectively [8].

The terpenoid test is shown in Figure 1a, the yellow color of the *n*-hexane and MeOH extracts indicates the presence of terpenoids, while the green color in the methylene chloride and ethyl acetate extracts indicates that they contain steroids. In Figure 1b, the brown color indicates the extract contains alkaloids. Based on the test results, *M. malabathricum* leaves contain alkaloids in the extracts of MeOH, methylene chloride, *n*-hexane, as well as ethyl acetate. Meanwhile, Figure 1c shows that MeOH, methylene chloride, *n*-hexane, as well as ethyl acetate extracts contain flavonoids. The yellow color on the flavonoid test indicates that the extract contains flavonoids.

Jofry et. al., (2012) reported that *M. malabathricum* leaves extract contains flavonoids, triterpenoids, tannins, saponins, steroids, alkaloids, and phenolics [13]. Plants have bioactivity because they have secondary metabolites. *M. malabathricum* displays a range of bioactivities, including antiviral, cytotoxic, antioxidant, cancer-fighting, antihypertensive, antinociceptive, anti-inflammatory, antipyretic, antibacterial, and antifungal properties [3].




FIGURE 1. Terpenoid (a), alkaloid (b), and flavonoid (c) test results on extracts of *n*-hexane (HX), methylene chloride (MC), ethyl acetate (EA), and methanol (MeOH).

***In vitro* Cytotoxic Assay**

Using the PrestoBlue technique, the methanol extract's *in vitro* cytotoxicity toward the MCF-7, HeLa, A549, B16, and HT29 cancer cell lines was evaluated. With IC_{50} values ranging from 1.43 to 327.37 $\mu\text{g/mL}$, Table 2 demonstrates that the methanol extract is cytotoxic against all five human cancer cell lines.

TABLE 2. Methanol extract's cytotoxicity in vitro against five cancer cell lines

Samples	IC_{50} ($\mu\text{g/mL}$)				
	MCF-7	HeLa	A549	B16	HT29
MeOH extract	327.37 \pm 0.67	327.05 \pm 0.48	304.46 \pm 1.93	319.21 \pm 0.67	1.43 \pm 0.19
Cisplatin	15.96 \pm 0.13	5.72 \pm 0.50	150.58 \pm 0.27	12.97 \pm 0.11	2.98 \pm 0.48

The data describe the mean \pm SD of two experiments.




FIGURE 2. The MCF-7 cells morphology was treated with different doses of *M. malabathricum* leaf methanol extract.




FIGURE 3. The HeLa cells' morphology was treated with various amounts of methanol extract from *M. malabathricum* leaves.




FIGURE 4. The A549 cells morphology was treated with various doses of methanol extract from *M. malabathricum* leaves.




FIGURE 5. The B16 cells morphology was treated with various doses of methanol extract from *M. malabathricum* leaves.




FIGURE 6. The HT29 cells morphology was treated with various doses of *M. malabathricum* leaves methenol extract.

Figures 2–6 show the morphology of MCF-7, HeLa, A549, B16, and HT29 cells after treatment with the methanol extract. The cytotoxicity effect of the extract depends on the concentration, where the cytotoxicity

increases with increasing the concentration of the extract. The appearance of cells resembled needles closely packed together at low concentrations. At the same time, the cells' morphology at high concentrations of the extract was spherical and floating, this indicates that many cells died. The anticancer properties observed in this investigation regarding the *M. malabathricum* extract could be explained by the presence of combination of polyphenols including tannins, flavonoids, glycosides, and terpenoids as well as other substances, all of which are found in *M. malabathricum* [14]. In previous research, the methanol extract contained relatively high total phenolics and flavonoids with values of 183.71 ± 0.11 (mg GAE/g extract), 23.18 ± 0.05 TFC (mg QE/g extract) respectively [8], hence, the methanol extract used for cytotoxicity test. The extract demonstrated noteworthy activity against HT29 cancer cells, as indicated by its IC_{50} values being twice as strong as those of cisplatin, the positive control. Due to the presence of flavonoids in the methanol extract, it was discovered to have the greatest cytotoxicity against the HT29 cell line [7]. Antioxidants, antidiabetic, and anticancer characteristics are only a few of the bioactivities that flavonoid and as well as phenolic compounds have been linked to [15]. It has been demonstrated that certain flavonoids serve as antiproliferative agents in cancer cells and induce apoptosis in human tumor cells [6]. With their chemically diverse structures, bioactive compounds from plants hold the promise to treat cancer with less adverse effects than current treatments [15]. The methanol extract has the potential to be used in the HT29 cells treatment, according to the results of the cytotoxicity tests.

CONCLUSION

The *M. malabathricum* leaves extract phytochemical screening revealed that the extract contained secondary metabolites (terpenoids, steroids, alkaloids, and flavonoids). With IC_{50} values ranging from 1.43 to 327.37 $\mu\text{g/mL}$, the methanol extract of *M. malabathricum* leaves showed cytotoxic action against a number of cancer cell lines, including MCF-7, HeLa, A549, B16, and HT29. In particular, the extract demonstrated a 2-fold stronger IC_{50} value against HT29 cells compared to cisplatin, indicating its potent activity against HT29 cancer cells. These findings imply that *M. malabathricum* leaf methanolic extract has the potential to be an important source of anticancer drugs.

ACKNOWLEDGMENTS

The authors would like to acknowledge the Directorate of Research and Community Service and Directorate General of Strengthening Research and Development, Ministry of Research, Technology and Higher Education of Republic Indonesia for the financial support for Doctoral Dissertation Research with contract number 828/PKS/ITS/2021.

REFERENCES

1. D. Buyinza, L. J. Yang, S. Derese, A. Ndakala, P. Coghi, M. Heydenreich, V. K. W. Wong, H. M. Möller, and A. Yenesew, *Nat. Prod. Res.* 35, 2744-2747 (2019).
2. R. Fang, P. J. Houghton, and P. J. Hylands, *J. Ethnopharmacol.* 118, 257–263 (2008).
3. N. A. Roslen, N. A. M. Alewi, H. Ahamada, and M. S. B. A. Rasad, *Asian Pac. J. Trop. Biomed.* 4(7), 545-548 (2014).
4. Z. A. Zakaria, R. N. S. R. M. Nor, G. H. Kumar, Z. D. F. A. Ghani, M. R. Sulaiman, G. R. Devi, A. M. M. Jais, M. N. Somchit, and C. A. Fatimah, *Can. J. Physiol. Pharmacol.* 84, 1291-1299 (2006).
5. D. P. Giri and M. Rajbhandari, *J. Institute Sci. Technol.* 23, 18-25 (2018).
6. D. Susanti, H. M. Sirat, F. Ahmad, R. M. Ali, N. Aimi, and M. Kitajima, *Food Chem.* 103, 710-716 (2007).
7. N. E. Kamsani, Z. A. Zakaria, N. L. Md Nasir, N. Mohtarrudin, and N. B. M. Alitheen, *Evidence-Based Complement. Altern. Med.* 2019, 5207958 (2019).

8. M. Idris, A. S. Purnomo, F. Martak, and S. Fatmawati, *Journal of Hunan University Natural Sciences*. 49 (2022).
9. G. A. Ayoola, H. A. B. Coker, S. A. Adesegun, A. A. Adepoju-Bello, K. Obaweya, E. C. Ezennia, and T. O. Atangbayila, *Trop. J. Pharm. Res.* 7(3), 1019-1024 (2008).
10. N. Kancherla, A. Dhakshinamoothi, K. Chitra, and R. B. Komaram, *Maedica (Bucur)*, 14(4), 350-356 (2019).
11. K. Ikhiri, D. Boureima, and D. D. Dan-Koulodo. *Int. J. Pharmacog.* 30(4), 251-262 (1992).
12. Nurlelasari, I. Rahmayanti, S. Salam, A. Safari, D. Harneti, R. Maharani, A. T. Hidayat, M. Tanjung, R. Retnowati, Y. Shiono, and U. Supratman, *Appl. Biol. Chem.* 64, 35 (2021).
13. S. M. Joffry, N. J. Yob, M. S. Rofiee, M. M. R. M. M. Affandi, Z. Suhaili, F. Othman, A. M. Akim, M. N M. Desa, and Z. A. Zakaria, *Evidence-Based Complement. Altern. Med.* 2012, 48 (2012).
14. N. Elumalai, P. Ayyakkannu, S. Palanivelu and S. Panchanadham, *RSC Adv.* 5, 23125–23133 (2015).
15. M. Idris, E. R. Sukandar, A. S. Purnomo, F. Martak, and S. Fatmawati, *RSC Adv.* 12, 25697 (2022).

This License to Publish must be signed and returned to the Proceedings Editor before the manuscript can be published. If you have questions about how to submit the form, please contact the AIP Publishing Conference Proceedings office (confproc@aip.org). For questions regarding the copyright terms and conditions of this License, please contact AIP Publishing's Office of Rights and Permissions, 1305 Walt Whitman Road, Suite 300, Melville, NY 11747-4300 USA; Phone 516-576-2268; Email: rights@aip.org. Article

Title ("Work"):

Phytochemical Screening and Cytotoxicity of *Melastoma malabathricum* L. Leaves Extracts Against MCF-7, HeLa, A549, B16, and HT29 Cells

(Please indicate the final title of the Work. Any substantive changes made to the title after acceptance of the Work may require the completion of a new agreement.)

All Author(s):

Muddatstsir Idris, Adi Setyo Purnomo, Fahimah Martak, Sri Fatmawati

(Please list **all** the authors' names in order as they will appear in the Work. All listed authors must be fully deserving of authorship and no such authors should be omitted. For large groups of authors, attach a separate list to this form.)

Title of Conference: _____

Name(s) of Editor(s) _____

All Copyright Owner(s), if not Author(s):

(Please list **all** copyright owner(s) by name. In the case of a Work Made for Hire, the employer(s) or commissioning party(ies) are the copyright owner(s). For large groups of copyright owners, attach a separate list to this form.)

Copyright Ownership and Grant of Rights

For the purposes of this License, the "Work" consists of all content within the article itself and made available as part of the article, including but not limited to the abstract, tables, figures, graphs, images, and multimedia files, as well as any subsequent errata. "Supplementary Material" consists of material that is associated with the article but linked to or accessed separately (available electronically only), including but not limited to data sets and any additional files.

This Agreement is an Exclusive License to Publish not a Transfer of Copyright. Copyright to the Work remains with the Author(s) or, in the case of a Work Made for Hire, with the Author(s)' employer(s). AIP Publishing LLC shall own and have the right to register in its name the copyright to the proceedings issue or any other collective work in which the Work is included. Any rights granted under this License are contingent upon acceptance of the Work for publication by AIP Publishing. If for any reason and at its own discretion AIP Publishing decides not to publish the Work, this License is considered void.

Each Copyright Owner hereby grants to AIP Publishing LLC the following irrevocable rights for the full term of United States and foreign copyrights (including any extensions):

1. The exclusive right and license to publish, reproduce, distribute, transmit, display, store, translate, edit, adapt, and create derivative works from the Work (in whole or in part) throughout the world in all formats and media whether now known or later developed, and the nonexclusive right and license to do the same with the Supplementary Material.
2. The right for AIP Publishing to freely transfer and/or sublicense any or all of the exclusive rights listed in #1 above. Sublicensing includes the right to authorize requests for reuse of the Work by third parties.
3. The right for AIP Publishing to take whatever steps it considers necessary to protect and enforce, at its own expense, the exclusive rights granted herein against third parties.

Author Rights and Permitted Uses

Subject to the rights herein granted to AIP Publishing, each Copyright Owner retains ownership of copyright and all other proprietary rights such as patent rights in the Work.

Each Copyright Owner retains the following nonexclusive rights to use the Work, without obtaining permission from AIP Publishing, in keeping with professional publication ethics and provided clear credit is given to its first publication in an AIP Publishing proceeding. Any reuse must include a full credit line acknowledging AIP Publishing's publication and a link to the Version of Record (VOR) on AIP Publishing's site.

Each Copyright Owner may:

4. Use the AM for posting within scientific collaboration networks (SCNs). For a detailed description of our policy on posting to SCNs, please see our Web Posting Guidelines (<https://publishing.aip.org/authors/web-posting-guidelines>).
5. Reprint the Version of Record (VOR) in print collections written by the Author, or in the Author's thesis or dissertation. It is understood and agreed that the thesis or dissertation may be made available electronically on the university's site or in its repository and that copies may be offered for sale on demand.
6. Reproduce copies of the VOR for courses taught by the Author or offered at the institution where the Author is employed, provided no fee is charged for access to the Work.
7. Use the VOR for internal training and noncommercial business purposes by the Author's employer.
8. Use the VOR in oral presentations made by the Author, such as at conferences, meetings, seminars, etc., provided those receiving copies are informed that they may not further copy or distribute the Work.
9. Distribute the VOR to colleagues for noncommercial scholarly use, provided those receiving copies are informed that they may not further copy or distribute the Work.
10. Post the VOR to their personal web page or their employer's web page 12 months after publication by AIP Publishing.
11. Deposit the VOR in an institutional or funder-designated repository 12 months after publication by AIP Publishing.
12. Update a prior posting with the VOR on a noncommercial server such as arXiv, 12 months after publication by AIP Publishing.

Author Warranties

Each Author and Copyright Owner represents and warrants to AIP Publishing the following:

1. The Work is the original independent creation of each Author and does not infringe any copyright or violate any other right of any third party.
2. The Work has not been previously published and is not being considered for publication elsewhere in any form, except as a preprint on a noncommercial server such as arXiv, or in a thesis or dissertation.
3. Written permission has been obtained for any material used from other sources and copies of the permission grants have been supplied to AIP Publishing to be included in the manuscript file.
4. All third-party material for which permission has been obtained has been properly credited within the manuscript.
5. In the event that the Author is subject to university open access policies or other institutional restrictions that conflict with any of the rights or provisions of this License, such Author has obtained the necessary waiver from his or her university or institution.

This License must be signed by the Author(s) and, in the case of a Work Made for Hire, also by the Copyright Owners. One Author/Copyright Owner may sign on behalf of all the contributors/owners only if they all have authorized the signing, approved of the License, and agreed to be bound by it. The signing Author and, in the case of a Work Made for Hire, the signing Copyright Owner warrants that he/she/it has full authority to enter into this License and to make the grants this License contains.

1. The Author must please sign here (except if an Author is a U.S. Government employee, then please sign under #3 below):

	Sri Fatmawati	8 July 2023
Author(s) Signature	Print Name	Date

2. The Copyright Owner (if different from the Author) must please sign here:

Name of Copyright Owner	Authorized Signature and Title	Date

3. If an Author is a U.S. Government employee, such Author must please sign below. The signing Author certifies that the Work was written as part of his/her official duties and is therefore not eligible for copyright protection in the United States.

1. Reprint portions of the Work (excerpts, figures, tables) in future works created by the Author, in keeping with professional publication ethics.
2. Post the Accepted Manuscript (AM) to their personal web page or their employer's web page immediately after acceptance by AIP Publishing.
3. Deposit the AM in an institutional or funder-designated repository immediately after acceptance by AIP Publishing.

Name of U.S. Government Institution (e.g., Naval Research Laboratory, NIST)

Author Signature

Print Name

Date

PLEASE NOTE: NATIONAL LABORATORIES THAT ARE SPONSORED BY U.S. GOVERNMENT AGENCIES BUT ARE INDEPENDENTLY RUN ARE NOT CONSIDERED GOVERNMENT INSTITUTIONS. (For example, Argonne, Brookhaven, Lawrence Livermore, Sandia, and others.) Authors at these types of institutions should sign under #1 or #2 above.

If the Work was authored under a U.S. Government contract, and the U.S. Government wishes to retain for itself and others acting on its behalf, a paid-up, nonexclusive, irrevocable, worldwide license in the Work to reproduce, prepare derivative works from, distribute copies to the public, perform publicly, and display publicly, by or on behalf of the Government, please check the box below and add the relevant Contract numbers.

Contract #(s) _____ [1.16.1]

Accepted Manuscript (AM): The final version of an author's manuscript that has been accepted for publication and incorporates all the editorial changes made to the manuscript after submission and peer review. The AM does not yet reflect any of the publisher's enhancements to the work such as copyediting, pagination, and other standard formatting.

arXiv: An electronic archive and distribution server for research article preprints in the fields of physics, mathematics, computer science, quantitative biology, quantitative finance, and statistics, which is owned and operated by Cornell University, <http://arxiv.org/>.

Commercial and noncommercial scholarly use: *Noncommercial* scholarly uses are those that further the research process for authors and researchers on an individual basis for their own personal purposes. They are author-to-author interactions meant for the exchange of ideas. *Commercial* uses fall outside the author-to-author exchange and include but are not limited to the copying or distribution of an article, either in hard copy form or electronically, for resale or licensing to a third party; posting of the AM or VOR of an article by a site or service where an access fee is charged or which is supported by commercial paid advertising or sponsorship; use by a for-profit entity for any type of promotional purpose. Commercial uses require the permission of AIP Publishing.

Embargo period: The period of time during which free access to the full text of an article is delayed.

Employer's web page: A web page on an employer's site that highlights the accomplishments and research interests of the company's employees, which usually includes their publications. (See also: Personal web page and Scholarly Collaboration Network).

Exclusive License to Publish: An exclusive license to publish is a written agreement in which the copyright owner gives the publisher exclusivity over certain inherent rights associated with the copyright in the work. Those rights include the right to reproduce the work, to distribute copies of the work, to perform and display the work publicly, and to authorize others to do the same. The publisher does not hold the copyright to the work, which continues to reside with the author. The terms of the AIP Publishing License to Publish encourage authors to make full use of their work and help them to comply with requirements imposed by employers, institutions, and funders.

Full Credit Line: AIP Publishing's preferred format for a credit line is as follows (you will need to insert the specific citation information in place of the capital letters): "Reproduced from [FULL CITATION], with the permission of AIP Publishing." A FULL CITATION would appear as: Journal abbreviation, volume number, article ID number or page number (year). For example: Appl. Phys. Lett. 107, 021102 (2015).

Institutional repository: A university or research institution's digital collection of articles that have been authored by its staff and which are usually made publicly accessible. As authors are encouraged and sometimes required to include their published articles in their institution's repository, the majority of publishers allow for deposit of the Accepted Manuscript for this purpose. AIP Publishing also allows for the VOR to be deposited 12 months after publication of the Work.

Journal editorial office: The contact point for authors concerning matters related to the publication of their manuscripts. Contact information for the journal editorial offices may be found on the journal websites under the "About" tab.

Linking to the Version of Record (VOR): To create a link to your article in an AIP Publishing journal or proceedings, you need to know the CrossRef digital object identifier (doi). You can find the doi on the article's abstract page. For instructions on linking, please refer to our Web Posting Guidelines at <https://publishing.aip.org/authors/web-posting-guidelines>.

National Laboratories: National laboratories are sponsored and funded by the U.S. Government but have independent nonprofit affiliations and employ private sector resources. These institutions are classified as Federally Funded Research and Development Centers (FFRDCs). Authors working at FFRDCs are not

considered U.S. Government employees for the purposes of copyright. The Master Government List of FFRDCs may be found at <http://www.nsf.gov/statistics/ffrdclist/>.

Personal web page: A web page that is hosted by the author or the author's institution and is dedicated to the author's personal research interests and publication history. An author's profile page on a social media site or scholarly collaboration network site is *not* considered a personal web page. (See also: Scholarly Collaboration Network; Employer's web page).

Peer X-Press: A web-based manuscript submission system by which authors submit their manuscripts to AIP Publishing for publication, communicate with the editorial offices, and track the status of their submissions. The Peer X-Press system provides a fully electronic means of completing the License to Publish. A hard copy of the Agreement will be supplied by the editorial office if the author is unable to complete the electronic version of the form. (Conference Proceedings authors will continue to submit their manuscripts and forms directly to the Conference Editors.)

Preprint: A version of an author's manuscript intended for publication but that has not been peer reviewed and does not reflect any editorial input or publisher enhancements.

Professional Publication Ethics: AIP Publishing provides information on what it expects from authors in its "Statement of ethics and responsibilities of authors submitting to AIP Publishing journals" (<http://publishing.aip.org/authors/ethics>). AIP Publishing is also a member of the Committee on Publication Ethics (COPE) (<http://publicationethics.org/>), which provides numerous resources and guidelines for authors, editors, and publishers with regard to ethical standards and accepted practices in scientific publishing.

Scholarly Collaboration Network (SCN): Professional networking sites that facilitate collaboration among researchers as well as the sharing of data, results, and publications. SCNs include sites such as Academia.edu, ResearchGate, and Mendeley, among others.

Supplementary Material: Related material that has been judged by peer review as being relevant to the understanding of the article but that may be too lengthy or of too limited interest for inclusion in the article itself. Supplementary Material may include data tables or sets, appendixes, movie or audio clips, or other multimedia files.

U.S. Government employees: Authors working at Government organizations who author works as part of their official duties and who are not able to license rights to the Work, since no copyright exists. Government works are in the public domain within the United States.

Version of Record (VOR): The final published version of the article as it appears in the printed journal/proceedings or on the Scitation website. It incorporates all editorial input, is formatted in the publisher's standard style, and is usually viewed in PDF form.

Waiver: A request made to a university or institution to exempt an article from its open-access policy requirements. For example, a conflict may exist with any policy that requires the author to grant a nonexclusive license to the university or institution that enables it to license the Work to others. In all such cases, the Author must obtain a waiver, which shall be included in the manuscript file.

Work: The "Work" is considered all the material that comprises the article, including but not limited to the abstract, tables, figures, images, multimedia files that are directly embedded within the text, and the text itself. The Work does not include the Supplementary Material (see Supplementary Material above).

Work Made for Hire: Under copyright law, a work prepared by an employee within the scope of employment, or a work that has been specially ordered or commissioned for which the parties have agreed in writing to consider as a Work Made for Hire. The hiring party or employer is considered the author and owner of the copyright, not the person who creates the work.